Massimo Brunetti
Mario Negri Institute for Pharmacological Research
6 Papers
78 Citations
Massimo Brunetti is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Cost effectiveness & Health administration. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Costs of diabetes : a methodological analysis of the literature
TL;DR: A general consensus on COI studies is still remote, making the value of any comparison of results questionable, and some specific points that could help produce more reliable results on the costs of diabetes are suggested.
66
Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial.
Maria Grazia Franzosi,Massimo Brunetti,Roberto Marchioli,Rosa Maria Marfisi,Gianni Tognoni,Franco Valagussa +5 more
TL;DR: The cost effectiveness of long term treatment with n-3 PUFA is comparable with other drugs recently introduced in the routine care of secondary prevention after myocardial infarction, and should be added to the established routine practice, with additive costs.
58
Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy.
TL;DR: This economic evaluation demonstrated savings in healthcare expenditure with the use of an ACE inhibitor in patients with proteinuria, and captopril therapy was dominant, being at the same time more effective and less costly.
15
Analisi costi-efficacia del trattamento con n-3 PUFA nel post-infarto miocardico: i risultati dello studio GISSI-Prevenzione
Maria Grazia Franzosi,Massimo Brunetti,Roberto Marchioli,RosaMaria Marfisi,Gianni Tognoni,Franco Valagussa,Ricercatori del GISSI-Prevenzione +6 more
TL;DR: The cost-effectiveness of long term treatment with n-3 PUFA is comparable with other drugs recently introduced in the routine care of secondary prevention after MI, and this therapy should be added to the established routine practice, with additive costs.
1
Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.
Peter K. Schädlich,Josef Georg Brecht,Massimo Brunetti,Eva Pagano,Badrudin Rangoonwala,Eduard Huppertz +5 more
TL;DR: Results from this evaluation show that ramipril offers enormous savings from the perspective of the SHI provider (third-party payer) in Germany when added to the conventional treatment of patients with non-diabetic nephropathy and hypertension.